Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses. Under the terms of the agreement, Apotex…
Cumberland Pharmaceuticals Inc. announced today it has agreed to sell its line of branded pharmaceuticals to an affiliate of Apotex for $100 million in cash.…
Q1 2026 results (filed May 2026): net revenues $9.1M, net loss $3.3M (vs net income $1.2M prior-year quarter). Brand revenue: Kristalose $1.0M, Sancuso…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cumberland Pharmaceuticals (CPIX) agreed to sell its branded U.S. commercial business to an Apotex affiliate for $100M cash, retaining its ifetroban pipeline (DMD cardiomyopathy and systemic sclerosis programs). Subject to Cumberland shareholder approval.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Apotex Inc. / Cumberland Pharmaceuticals branded U.S. commercial business (this deal) | 2026 | $100M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2026 deals · Other deals